|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
World Health Organization, International
Agency for Research on Cancer, Cancer Fact Sheets. http://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf2018
4–September. 2020
|
|
3
|
Soslow RA: Histologic subtypes of ovarian
carcinoma: An overview. Int J Gynecol Pathol. 27:161–174.
2008.PubMed/NCBI
|
|
4
|
Machida H, Matsuo K, Yamagami W, Ebina Y,
Kobayashi Y, Tabata T, Kanauchi M, Nagase S, Enomoto T and Mikami
M: Trends and characteristics of epithelial ovarian cancer in Japan
between 2002 and 2015: A JSGO-JSOG joint study. Gynecol Oncol.
153:589–596. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee AW, Navajas EE and Liu L: Clear
differences in ovarian cancer incidence and trends by ethnicity
among Asian Americans. Cancer Epidemiol. 61:142–149. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shu CA, Zhou Q, Jotwani AR, Iasonos A,
Leitao MM Jr, Konner JA and Aghajanian CA: Ovarian clear cell
carcinoma, outcomes by stage: The MSK experience. Gynecol Oncol.
139:236–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Anglesio MS, Carey MS, Köbel M, Mackay H
and Huntsman DG; Vancouver Ovarian Clear Cell Symposium Speakers, :
Clear cell carcinoma of the ovary: A report from the first ovarian
clear cell symposium, June 24th, 2010. Gynecol Oncol. 121:407–415.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meyer T and Rustin GJ: Role of tumour
markers in monitoring epithelial ovarian cancer. Br J Cancer.
82:1535–1538. 2000.PubMed/NCBI
|
|
9
|
Kudoh K, Kikuchi Y, Kita T, Tode T, Takano
M, Hirata J, Mano Y, Yamamoto K and Nagata I: Preoperative
determination of several serum tumor markers in patients with
primary epithelial ovarian carcinoma. Gynecol Obstet Invest.
47:52–57. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sierko E, Wojtukiewicz MZ and Kisiel W:
The role of tissue factor pathway inhibitor-2 in cancer biology.
Semin Thromb Hemost. 33:653–659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyagi Y, Koshikawa N, Yasumitsu H, Miyagi
E, Hirahara F, Aoki I, Misugi K, Umeda M and Miyazaki K: cDNA
cloning and mRNA expression of a serine proteinase inhibitor
secreted by cancer cells: Identification as placental protein 5 and
tissue factor pathway inhibitor-2. J Biochem. 116:939–942. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rao CN, Reddy P, Liu Y, O'Toole E, Reeder
D, Foster DC, Kisiel W and Woodley DT: Extracellular
matrix-associated serine protease inhibitors (Mr 33,000, 31,000,
and 27,000) are single-gene products with differential
glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its
identity to tissue factor pathway inhibitor-2. Arch Biochem
Biophys. 335:82–92. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ogawa M, Yanoma S, Nagashima Y, Okamoto N,
Ishikawa H, Haruki A, Miyagi E, Takahashi T, Hirahara F and Miyagi
Y: Paradoxical discrepancy between the serum level and the
placental intensity of PP5/TFPI-2 in preeclampsia and/or
intrauterine growth restriction: Possible interaction and
correlation with glypican-3 hold the key. Placenta. 28:224–232.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karaszi K, Szabo S, Juhasz K, Kiraly P,
Kocsis-Deak B, Hargitai B, Krenacs T, Hupuczi P, Erez O, Papp Z, et
al: Increased placental expression of placental protein 5
(PP5)/tissue factor pathway inhibitor-2 (TFPI-2) in women with
preeclampsia and HELLP syndrome: Relevance to impaired trophoblast
invasion? Placenta. 76:30–39. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rao CN, Lakka SS, Kin Y, Konduri SD,
Fuller GN, Mohanam S and Rao JS: Expression of tissue factor
pathway inhibitor 2 inversely correlates during the progression of
human gliomas. Clin Cancer Res. 7:570–576. 2001.PubMed/NCBI
|
|
16
|
Rollin J, Iochmann S, Bléchet C, Hubé F,
Régina S, Guyétant S, Lemarié E, Reverdiau P and Gruelet Y:
Expression and methylation status of tissue factor pathway
inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer.
92:775–783. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sato N, Parker AR, Fukushima N, Miyagi Y,
Iacobuzio-Donahue CA, Eshleman JR and Gogginset M: Epigenetic
inactivation of TFPI-2 as a common mechanism associated with growth
and invasion of pancreatic ductal adenocarcinoma. Oncogene.
24:850–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo H, Lin Y, Zhang H, Liu J, Zhang N, Li
Y, Kong D, Tang Q and Ma D: Tissue factor pathway inhibitor-2 was
repressed by CpG hypermethylation through inhibition of KLF6
binding in highly invasive breast cancer cells. BMC Mol Biol.
8:1102007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nobeyama Y, Okochi-takada E, Furuta J,
Miyagi Y, Kikuchi K, Yamamoto A, Nakanishi Y, Nakagawa H and
Ushijima T: Silencing of tissue factor pathway inhibitor-2 gene in
malignant melanomas. Int J Cancer. 121:301–307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong C, Ng Y, Lee JM, Wong CC, Cheung O,
Chan C, Tung EK, Ching Y and Ng IO: Tissue factor pathway
inhibitor-2 as a frequently silenced tumor suppressor gene in
hepatocellular carcinoma. Hepatology. 45:1129–1138. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Y, Qin X, Zhou J, Tu Z, Bi X, Li W, Fan
X and Zhang Y: Tissue factor pathway inhibitor-2 inhibits the
growth and invasion of hepatocellular carcinoma cells and is
inactivated in human hepatocellular carcinoma. Oncol Lett.
2:779–783. 2011.PubMed/NCBI
|
|
22
|
Lavergne M, Jourdan ML, Blechet C,
Guyetant S, Pape AL, Heuze-Vourc'h N, Courty Y, Lerondel S, Sobilo
J, Iochmann S and Reverdiau P: Beneficial role of overexpression of
TFPI-2 on tumour progression in human small cell lung cancer. FEBS
Open Bio. 3:291–301. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kempaiah P, Chand HS and Kisiel W: Human
tissue factor pathway inhibitor-2 is internalized by cells and
translocated to the nucleus by the importin system. Arch Biochem
Biophys. 482:58–65. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang G, Zeng Y, Chen S, Li D, Li W, Zhou
Y, Singer RH and Gu W: Localization of TFPI-2 in the nucleus
modulates MMP-2 gene expression in breast cancer cells. Sci Rep.
7:135752017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Arakawa N, Miyagi E, Nomura A, Morita E,
Ino Y, Ohtake N, Miyagi Y, Hirahara F and Hirano H: Secretome-Based
identification of TFPI2, A novel serum biomarker for detection of
ovarian clear cell adenocarcinoma. J Proteome Res. 12:4340–4350.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arakawa N, Kobayashi H, Yonemoto N,
Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y,
Hirahara F, et al: Clinical significance of tissue factor pathway
inhibitor 2, a serum biomarker candidate for ovarian clear cell
carcinoma. PLoS One. 11:e01656092016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pearce CL, Templeman C, Rossing MA, Lee A,
Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund
KG, et al: Association between endometriosis and risk of
histological subtypes of ovarian cancer: A pooled analysis of
case-control studies. Lancet Oncol. 13:385–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cinti S, Matteis RD, Picó C, Ceresi E,
Obrador A, Maffeis C, Oliver J and Palou A: Secretory granules of
endocrine and chief cells of human stomach mucosa contain leptin.
Int J Obes Relat Metab Disord. 24:789–793. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wojtukiewicz MZ, Sierko E, Zimnoch L,
Kozlowski L and Kisiel W: Immunohistochemical localization of
tissue factor pathway inhibitor-2 in human tumor tissue. Thromb
Haemost. 90:140–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Altmäe S, Salumets A, Bjuresten K, Kallak
TK, Wånggren K, Landgren BM, Hovatta O and Stavreus-Evers A: Tissue
factor and tissue factor pathway inhibitors TFPI and TFPI2 in human
secretory endometrium-possible link to female infertility. Reprod
Sci. 18:666–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhai LL, Cai CY, Wu Y and Tang ZG:
Correlation and prognostic significance of MMP-2 and TFPI-2
differential expression in pancreatic carcinoma. Int J Clin Exp
Pathol. 8:682–691. 2015.PubMed/NCBI
|
|
33
|
Xu C, Wang H, He H, Zheng F, Chen Y, Zhang
J, Lin X, Ma D and Zhang H: Low expression of TFPI-2 associated
with poor survival outcome in patients with breast cancer. BMC
Cancer. 13:1182013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sprecher CA, Kisiel W, Mathewes S and
Foster DC: Molecular cloning, expression, and partial
characterization of a second human tissue-factor-pathway inhibitor.
Proc Natl Acad Sci USA. 91:3353–3357. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang G, Huang W, Li W, Chen S, Chen W,
Zhou Y, Peng P and Gu W: TFPI-2 suppresses breast cancer cell
proliferation and invasion through regulation of ERK signaling and
interaction with actinin-4 and myosin-9. Sci Rep. 8:144022018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Köbel M, Kalloger SE, Carrick J, Huntsman
D, Asad H, Oliva E, Ewanowich CA, Soslow RA and Gilks CB: A limited
panel of immunomarkers can reliably distinguish between clear cell
and high-grade serous carcinoma of the ovary. Am J Surg Pathol.
33:14–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang W, Cheng X, Ji J, Zhang J and Li Q:
The application value of HNF-1β transcription factor in the
diagnosis of ovarian clear cell carcinoma. Int J Gynecol Pathol.
35:66–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yamashita Y, Nagasaka T, Naiki-Ito A, Sato
S, Suzuki S, Toyokuni S, Ito M and Takahashi S: Napsin A is a
specific marker for ovarian clear cell adenocarcinoma. Mod Pathol.
28:111–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maeda D, Ota S, Takazawa Y, Aburatani H,
Nakagawa S, Yano T, Taketani Y, Kodama T and Fukayama M: Glypican-3
expression in clear cell adenocarcinoma of the ovary. Mod Pathol.
22:824–832. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
The Human Protein Atlas: TFPI2. https://www.proteinatlas.org/ENSG00000105825-TFPI2April
8–2020
|
|
41
|
Vadivel K, Ponnuraj SM, Kumar Y, Zaiss AK,
Bunce MW, Camire RM, Wu L, Evseenko D, Herschman HR, Bajaj MS and
Bajaj SP: Platelets contain tissue factor pathway inhibitor-2
derived from megakaryocytes and inhibits fibrinolysis. J Biol Chem.
289:31647–31661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rao CN, Cook B, Liu Y, Chilukuri K, Stack
MS, Foster DC, Kisiel W and Woodley DT: HT-1080 fibrosarcoma cell
matrix degradation and invasion are inhibited by the
matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int
J Cancer. 76:749–756. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jin M, Udagawa K, Miyagi E, Nakazawa T,
Hirahara F, Yasumitsu H, Miyazaki K, Nagashima Y, Aoki I and Miyagi
Y: Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI
decreases the invasive potential of human choriocarcinoma cells in
vitro and in vivo. Gynecol Oncol. 83:325–333. 2001. View Article : Google Scholar : PubMed/NCBI
|
